SLC5A2 and diabetic kidney disease: Research extensively demonstrated the critical involvement of PT cells in the pathogenesis of early and late DKD (Gilbert, 2017; Zeni et al., 2017), while RAS blockade, SGLT2 inhibitors are all using PT cells as the main target of action (Sinha and Agarwal, 2019; Wang et al., 2023; Zhu et al., 2023).